NASDAQ:MIST Milestone Pharmaceuticals (MIST) Stock Price, News & Analysis $0.71 -0.09 (-10.98%) Closing price 10/16/2026 04:00 PM EasternExtended Trading$0.71 0.00 (-0.04%) As of 10/16/2026 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC Filings About Milestone Pharmaceuticals Stock (NASDAQ:MIST) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MIST alerts:Sign Up Key Stats Today's Range$0.70▼$0.8050-Day Range$0.71▼$1.2752-Week Range$0.70▼$3.06Volume974,359 shsAverage Volume1.12 million shsMarket Capitalization$88.06 millionP/E RatioN/ADividend YieldN/APrice Target$6.40Consensus RatingModerate Buy Company Overview Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s lead product candidate is etripamil, a short-acting calcium channel blocker formulated as a nasal spray and designed for rapid, patient-administered treatment. Etripamil has been studied primarily for paroxysmal supraventricular tachycardia (PSVT), a condition characterized by episodes of abnormally rapid heart rate. The product is intended to provide patients with an option for treating episodes outside of a hospital or clinic, potentially reducing the need for emergency medical intervention. Milestone has also evaluated etripamil in other cardiovascular settings, including the management of certain blood-pressure-related conditions. Founded in 2013, Milestone Pharmaceuticals conducts its research and development activities in North America and has advanced etripamil through clinical development programs intended to support regulatory review. The company is headquartered in Montreal, Quebec, and has been led by President and Chief Executive Officer Joseph Oliveto.AI Generated. May Contain Errors. Read More Milestone Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreMIST MarketRank™: 2.02604442094 of 5 starsMilestone Pharmaceuticals scored higher than 41% of companies evaluated by MarketBeat, and ranked 654th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingMilestone Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 1 strong buy rating, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMilestone Pharmaceuticals has a consensus price target of $6.40, representing about 804.8% upside from its current price of $0.71.Amount of Analyst CoverageMilestone Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Milestone Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Milestone Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Milestone Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Milestone Pharmaceuticals is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMilestone Pharmaceuticals has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Milestone Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.08% of the float of Milestone Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverMilestone Pharmaceuticals has a short interest ratio ("days to cover") of 15.98, which indicates bearish sentiment.Change versus previous monthShort interest in Milestone Pharmaceuticals has recently increased by 3.53%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMilestone Pharmaceuticals does not currently pay a dividend.Dividend GrowthMilestone Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.51 News SentimentMilestone Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Milestone Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest10 people have searched for MIST on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Milestone Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders5.03% of the stock of Milestone Pharmaceuticals is held by insiders.Percentage Held by Institutions86.18% of the stock of Milestone Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Milestone Pharmaceuticals' insider trading history. Receive MIST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Milestone Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MIST Stock News HeadlinesMilestone Pharmaceuticals Inc. (MIST) - What Are Researchers Thinking About This Stock?October 16 at 2:15 AM | americanbankingnews.comMilestone Moves Etripamil AFib-RVR Program Forward With First European Patient; Stock UpOctober 9, 2026 | rttnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 18 at 1:00 AM | Behind the Markets (Ad)Milestone Pharmaceuticals Enrolls First EU Patient in Phase 3 Etripamil Trial in Atrial FibrillationOctober 9, 2026 | finance.yahoo.comMilestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical TrialOctober 9, 2026 | globenewswire.comMilestone Enrolls First Canadian Patient In Phase 3 For EtripamilSeptember 27, 2026 | rttnews.comMilestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVRSeptember 24, 2026 | globenewswire.comMilestone Wins China Approval for Etripamil Nasal SpraySeptember 4, 2026 | theglobeandmail.comSee More Headlines MIST Stock Analysis - Frequently Asked Questions How have MIST shares performed this year? Milestone Pharmaceuticals' stock was trading at $2.02 at the start of the year. Since then, MIST shares have decreased by 65.0% and is now trading at $0.7073. How were Milestone Pharmaceuticals' earnings last quarter? Milestone Pharmaceuticals Inc. (NASDAQ:MIST) posted its earnings results on Wednesday, August, 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.02. The business earned $0.56 million during the quarter, compared to analyst estimates of $0.82 million. Read the conference call transcript. When did Milestone Pharmaceuticals IPO? Milestone Pharmaceuticals (MIST) raised $82 million in an initial public offering on Thursday, May 9th 2019. The company issued 5,500,000 shares at $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. Who are Milestone Pharmaceuticals' major shareholders? Top institutional shareholders of Milestone Pharmaceuticals include RVW Wealth LLC (0.92%) and Valeo Financial Advisors LLC (0.12%). Insiders that own company stock include Joseph Oliveto, Lorenz Muller, David Bharucha and Jeffrey Edward Nelson. View institutional ownership trends. How do I buy shares of Milestone Pharmaceuticals? Shares of MIST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Milestone Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Milestone Pharmaceuticals investors own include iBio (IBIO), Iovance Biotherapeutics (IOVA), NVIDIA (NVDA), Tonix Pharmaceuticals (TNXP), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD) and NIO (NIO). Company Calendar Last Earnings8/12/2026Today10/18/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MIST's financial health is in the Red zone, according to TradeSmith. MIST has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MIST CIK1408443 Webwww.milestonepharma.com Phone(514) 336-0444FaxN/AEmployees38Year Founded2005Price Target and Rating Average Price Target for Milestone Pharmaceuticals$6.40 High Price Target$8.00 Low Price Target$3.00 Potential Upside/Downside+804.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$63.06 million Net MarginsN/A Pretax Margin-3,657.42% Return on Equity-288.33% Return on Assets-58.27% Debt Debt-to-Equity Ratio3.25 Current Ratio8.13 Quick Ratio7.92 Sales & Book Value Annual Sales$2.34 million Price / Sales37.58 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book1.81Miscellaneous Outstanding Shares124,498,000Free Float118,236,000Market Cap$88.06 million OptionableOptionable Beta1.01 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:MIST) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIST Stock Alerts